Acceptability of risk-stratified breast screening: Effect of the order of presenting risk and benefit information.


Journal

Journal of medical screening
ISSN: 1475-5793
Titre abrégé: J Med Screen
Pays: England
ID NLM: 9433359

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 3 10 2019
medline: 16 1 2021
entrez: 3 10 2019
Statut: ppublish

Résumé

To test whether reduced-frequency risk-stratified breast screening would be perceived more favourably by transposing the order of information on benefits and risks. After reading vignettes describing non-stratified three-yearly screening and a risk-stratified alternative with five-yearly invitations for women at low risk, 698 women completed an online survey. Participants were allocated at random to information on screening benefits followed by risks, or vice versa, and asked to state preferences for either screening system. Participants also rated perceived magnitude of screening benefits and risks, and breast cancer susceptibility. Binomial logistic regression did not find order effects on preferences (p = 0.533) or perceived benefits of screening (p = 0.780). Perceived screening risks were greater when risks were presented first (p < 0.0005). Greater perceived susceptibility was associated with lower proportions preferring risk-stratified screening (15% vs. 39% in highest and lowest groups; p = 0.002), as were greater perceived screening benefits (e.g. 13% vs. 45% in highest and lowest groups; p < 0.0005). No information order effect on preferences was observed. Information order did affect screening risk perceptions. Efforts to improve perceptions may need to be more intensive than those tested. Women perceiving themselves as high risk or perceiving greater benefits of screening may be particularly averse to less frequent screening.

Identifiants

pubmed: 31575328
doi: 10.1177/0969141319877669
doi:

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

52-56

Subventions

Organisme : Cancer Research UK
ID : 14134
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1418/A14134
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C7492/A17219
Pays : United Kingdom

Auteurs

Alex Ghanouni (A)

Research Department of Behavioural Science and Health, University College London, London, UK.

Jo Waller (J)

Research Department of Behavioural Science and Health, University College London, London, UK.

Sandro T Stoffel (ST)

Research Department of Behavioural Science and Health, University College London, London, UK.

Ivo Vlaev (I)

Warwick Business School, University of Warwick, Coventry, UK.

Christian von Wagner (C)

Research Department of Behavioural Science and Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH